Project Grant K08CA300921
Award Date 9/3/25
Completion Date 8/31/30
Dollars Obligated $242K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This federal Project Grant award of $846,982 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports a research project titled "Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy" at Beth Israel Deaconess Medical Center, Inc. (Bidmc) in Boston, Massachusetts. The research aims to advance the understanding of how the PD-1:SHP-2 axis in hematopoietic stem and progenitor cells impacts the differentiation and function of...
- This federal Project Grant award of $312,892 was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The grant supports research at Duke University to study the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to understand how ILC3s impact the effectiveness of immune checkpoint inhibitor (ICI) therapy for advanced melanoma patients, as the majority do not respond to ICI treatment....
- This $549,460 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Florida to study the role of the BCL11B transcription factor in regulating CD8+ T cell response and memory in tumor microenvironments. The award aims to establish the transcriptional programs and epigenomic landscape controlled by BCL11B in mouse T cells, with the goal of understanding...
- The federal Project Grant award titled "HARNESSING B CELLS AFTER STEM CELL TRANSPLANT TO PRODUCE NOVEL CAR-TS" is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for a total of $415,257. The project period runs from July 3, 2025 to June 30, 2027. The award aims to leverage insights into B cell tolerance mechanisms after hematopoietic stem cell transplantation to engineer less toxic, more targeted immune cells that can eradicate hematological...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $818,625 to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct a randomized trial evaluating cardioprotective strategies for patients with diffuse large B-cell lymphoma (DLBCL) who have pre-existing cardiomyopathy or prior anthracycline exposure. The primary objective is to determine whether the infusional cardioprotective strategies of dexrazoxane or liposomal doxorubicin...
- This federal Project Grant award of $223,176, granted by the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), will fund research to investigate the role of SMARCAL1 depletion in promoting increased immunogenicity in alternative lengthening of telomeres (ALT)-positive high-grade gliomas. The overarching goal is to examine how therapeutic targeting of SMARCAL1, an annealing helicase, can lead to tumor-specific DNA damage, inflammation, and an enhanced immune...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $127,629 to Harvard T.H. Chan School of Public Health to elucidate the role of both germline and somatic human leukocyte antigen (HLA) variations in cellular immunity and the efficacy of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer. The research aims to leverage multi-omic data (genetics, genomics, transcriptomics, proteomics) from over 80,000 NSCLC...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...
- This $858,186 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports a research project titled "Decoding T Cell Clonotypes, Biology and Predictive Biomarkers Associated with Immune Checkpoint Myocarditis." The project aims to investigate the mechanisms underlying immune-related myocarditis, a potentially fatal adverse event associated with immune checkpoint inhibitor cancer therapies. Using...
- This Project Grant award from the National Institutes of Health's (NIH) National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $901,205 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct genome-wide studies examining how tumor immune editing in early-stage cancers leads to immune evasion and suppression. The research aims to identify key genes, pathways, and processes that are epigenetically repressed during early tumor...